… bevacizumab but whether bevacizumab adds to the efficacy of a triplet cannot be concluded
from these studies [16]. In the randomized phase II OLIVIA trial [17], in which mCRC patients …

… angiogenic therapies have improved colorectal cancer prognosis within the past 15 years.
Bevacizumab demonstrated efficacy … that a different tumor angiogenesis inhibitor could be …

… As first-line therapy, bevacizumab in combination with 5FU monotherapy or IFL (an
outmoded bolus regimen combining irinotecan and 5FU), substantially improved efficacy with a …

… angiogenesis inhibition may require targeting alternate angiogenic pathways in combination
with bevacizumab… We report the efficacy and safety of bevacizumab in combination with …

… At present, a head-to-head randomized clinical study comparing the efficacy of these three
angiogenesis inhibitors in this setting has not been undertaken. Moreover, useful biomarkers …

… , we realise that the contribution of bevacizumab to the efficacy of the treatment clearly varies
dependent on the chemotherapy regimen. The addition of bevacizumab to infusional 5-FU …

… and the first approved angiogenesis inhibitor. Marking the … Initially approved for treatment
of metastatic colorectal cancer in … therapy, both due to its established efficacy in approved …

… lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2
(… The safety and efficacy analyses were based on the randomized portion of this study only. …

… of dual angiogenesis inhibition with sorafenib … colorectal cancer, the role of BEV was recently
further emphasized with the positive findings of a phase III trial that investigated the efficacy …

… bevacizumab but whether bevacizumab adds to the efficacy of a triplet cannot be concluded
from these studies [16]. In the randomized phase II OLIVIA trial [17], in which mCRC patients …